Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
138
resultados
Última actualización
02/08/2025 [07:22:00]
Resultados 125 a 138 de 138
Resumen de: CN119438591A
本申请提供了一种蛋白标志物在制备检测炎症性肠病的检测产品中的应用。其中，蛋白标志物选自如下任意一个或多个蛋白分子：MRPL43、ECHS1、TLN2、ENO3、NCSTN、CTSH、CKMT1、TUBA4A、DYNC1H1、PDLIM3、GLB1及PMPCA。本申请通过实验证明了上述12个蛋白的瓜氨酸水平与炎症性肠病高度关联，因而可将其中的一个或多个作为蛋白标志物来制备检测炎症性肠病的检测产品(比如检测或诊断试剂盒等)。基于上述蛋白标志物的检测产品有助于实现尽早检测和无创检测，快捷、方便、准确。
Resumen de: CN119391523A
The invention discloses an in-vitro bionic intestinal barrier injury micro-physiological system. The device comprises a stomach digestion simulation system, a small intestine digestion simulation system, a small intestine interaction simulation system, a large intestine glycolysis simulation system and a large intestine interaction simulation system. According to the invention, the physicochemical environment for digestion of patients with inflammatory bowel diseases (IBD) is simulated by adjusting parameters such as pH, and the physiological system of the patients with IBD is simulated through human-derived organs and microorganisms. The in-vitro substitution model not only simulates gastrointestinal digestion, absorption and glycolysis processes of a patient with intestinal barrier injury in vitro, but also simulates interaction between food and metabolites thereof and intestinal tracts through introduction of organoids. The model can be used for exploring the metabolic process or toxic effect of food in the body of a patient suffering from intestinal barrier injury, evaluating the bioaccessibility, metabolic fate, interaction with microorganisms and influence on intestinal physiology of the food, and realizing precise risk assessment.
Resumen de: CN119390843A
本申请公开了生物医药技术领域的一种抗TL1A抗体及其制备方法和应用。其包括重链可变区和轻链可变区，其中，所述重链可变区包含氨基酸序列如SEQ ID NO:7~9所示的HCDR1、HCDR2和HCDR3；所述轻链可变区包含氨基酸序列如SEQ ID NO:10~12所示的LCDR1、LCDR2和LCDR3。该抗TL1A抗体的生物活性表征更优，且表位与传统抗TL1A抗体不同。
Resumen de: CN119395122A
本发明公开了一种用于炎症性肠病诊断的粪便生物标志物及其应用，该粪便生物标志物为肾上腺酸。本发明通过实验首次发现了肾上腺酸在IBD患者粪便样本中呈现上调，经检测发现肾上腺酸在IBD患者粪便标本中表达上调；进一步通过ROC曲线分析肾上腺酸相比于其他钙粘蛋白等炎症活动指标而言，具有较好的诊断敏感度和特异性。本发明为IBD的临床诊断提供了新的诊断标志物，以肾上腺酸作为IBD诊断的粪便生物标志物，用于炎症性肠病的诊断，具有检测精确度高、特异性和灵敏性高、方便快捷以及安全无创等优点，对判断IBD的活动状态、调整IBD患者的诊疗及管理等均具有重要意义。
Resumen de: WO2025024629A2
Provided herein are gene replacement approaches to restore HOXA11AS in the colon for patients with IBD, e.g., UC. Further, since HOXA11os levels inversely correlate with disease severity this lncRNA can also be used as a sensitive colon specific disease relevant biomarker.
Resumen de: US2025034613A1
Provided herein are engineered bacterial biosensors and methods of use thereof for detection of gastrointestinal disease, including inflammatory bowel disease.
Resumen de: CN119367543A
The invention discloses an application of an Ander-1 expression promoter in preparation of a medicine for preventing and treating ulcerative colitis. The invention discovers that the expression level of the And-1 is obviously reduced in the ulcerative colitis, the ulcerative colitis can be obviously aggravated by knocking out or silencing the And-1, and the ulcerative colitis can be obviously improved by overexpressing the And-1. Accordingly, technicians in the field can determine that the And-1 expression promoter can be used for preparing the medicine for preventing and treating the ulcerative colitis, and the And-1 gene or protein can be used as a medicine action target for screening and finding the medicine for preventing and treating the ulcerative colitis and a marker for diagnosis, treatment or prognosis of the ulcerative colitis; wherein the And-1 expression promoter is a substance for promoting And-1 expression, can be a nucleotide sequence for promoting And-1 expression or a carrier containing the nucleotide sequence, and can also be a small molecule compound, polypeptide or polysaccharide for promoting And-1 expression.
Resumen de: CN119345337A
The invention discloses a deubiquitination enzyme drug. The deubiquitination enzyme drug comprises a deubiquitination enzyme, an antioxidant nano-enzyme and a carrier for loading the deubiquitination enzyme and the antioxidant nano-enzyme. The deubiquitination enzyme medicine contains the deubiquitination enzyme and the antioxidant nano-enzyme, and the antioxidant nano-enzyme removes redundant ROS at the colon lesion, so that the biological activity of the deubiquitination enzyme can still be maintained in an inflammation microenvironment, and inflammation of the lesion is relieved. The invention further discloses a preparation method of the deubiquitination enzyme medicine. The preparation method is simple in process and short in time consumption. The invention also discloses application of the deubiquitinating enzyme medicine in preparation of medicines for treating and/or diagnosing inflammatory bowel diseases. The deubiquitinating enzyme medicine can activate an inertial cavitation mechanism through O2 microbubbles in an oxidative stress microenvironment of the inflammatory bowel disease, so that a photoacoustic signal is specifically generated, and accurate diagnosis of pathological changes of the inflammatory bowel disease and accurate treatment guided by photoacoustic imaging are realized.
Resumen de: CN119360942A
The invention provides an ulcerative colitis intestinal microbial marker, application thereof and an ulcerative colitis detection model, and belongs to the technical field of biology and biological medicine. By analyzing the composition of the intestinal microbe markers of the ulcerative colitis patient and monitoring the change of the intestinal microbe markers of the patient, the method can guide the adjustment of the intestinal microecology of the ulcerative colitis patient, makes a personalized treatment scheme for each UC patient, recovers the normal flora of the intestinal tract of the ulcerative colitis patient, and improves the treatment effect of the ulcerative colitis. The treatment effect is improved. The ulcerative colitis detection model can more accurately identify the intestinal flora difference between ulcerative colitis patients and healthy people, the ROC curve of the ulcerative colitis detection model is close to the upper left corner, the ulcerative colitis detection model has a high true positive rate under each threshold value, the AUC value reaches 0.8106, and the ulcerative colitis detection model can be used for detecting the ulcerative colitis. The ulcerative colitis detection model has good performance when distinguishing positive and negative samples.
Resumen de: CN119331783A
The invention provides a Villonella enteritidis strain and an application of the Villonella enteritidis strain. The preservation number of the Villonella enteritidis strain is GDMCC No: 65234. The invention also provides a preparation containing the Wehonor enteritidis, a culture method and application of the Wehonor enteritidis as a labeled microorganism or a target spot in preparation of drugs for screening diseases caused by the Wehonor enteritidis. According to the present invention, the virulence gene and the pathogenicity of the Wehonor enteritidis are analyzed, such that the Wehonor enteritidis has the potential pathogenicity for aggravating the inflammatory bowel disease, and the strain provides specificity in the aspects of biological characteristics, pathogenicity and the like compared with the Wehonor micrococcus, such that the cognition of the Wehonor micrococcus in the intestinal tract is new improved, and the Wehonor micrococcus enteritidis can be used for the treatment of the inflammatory bowel disease. Moreover, a new view angle and a new direction are provided for research on the effect of the Wehonor coccus in the intestinal diseases such as IBD (Infectious Bursal Disease).
Resumen de: US2025020660A1
The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).
Resumen de: US2025020667A1
Embodiments of the disclosure include systems, methods, and compositions for detection of imminent onset of a symptom of a gut inflammation medical condition. The disclosure also concerns microbial biosensors that detect a marker in the gut that is predictive of onset of at least one symptom of inflammatory bowel disease (IBD), for example, and such a sensor may include a promoter sensitive to the marker that is linked to expression of a detectable readout, such as in the feces of the individual with IBD.
Nº publicación: CN119307602A 14/01/2025
Solicitante:
NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV
\u5357\u65B9\u533B\u79D1\u5927\u5B66\u5357\u65B9\u533B\u9662
Resumen de: CN119307602A
The invention discloses application of an EphB3 gene as a biomarker in preparation of a Crohn disease detection product. According to the present invention, the expression of the EphB3 gene in the Crohn disease patient is significantly up-regulated, such that the EphB3 gene can be adopted as the Crohn disease-related biomarker, can specifically detect the Crohn disease infection, and has extremely high accuracy. Meanwhile, according to the application of a reagent for detecting EphB3 receptor expression in preparing a reagent for identifying and diagnosing the Crohn disease, the expression quantity of EphB3 in the intestinal mucosa of a patient suffering from the Crohn disease is remarkably increased compared with the expression quantity of EphB3 in the intestinal mucosa of a patient suffering from enterophthisis and a patient suffering from primary intestinal lymphoma, and the difference has statistical significance (Plt; therefore, the detection of the expression of the EphB3 can be used for differential diagnosis of Crohn's disease, intestinal tuberculosis and primary intestinal lymphoma, and has extremely high specificity and accuracy.
BOPI
Sede Electrónica
